Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Noven Pharms Inc	COMBIPATCH	estradiol; norethindrone acetate	FILM, EXTENDED RELEASE;TRANSDERMAL	020870	NDA	Noven Therapeutics, LLC	68968-0514-8	8 POUCH in 1 CARTON (68968-0514-8) / 1 PATCH in 1 POUCH / 3.5 d in 1 PATCH	1998-08-07
Noven Pharms Inc	COMBIPATCH	estradiol; norethindrone acetate	FILM, EXTENDED RELEASE;TRANSDERMAL	020870	NDA	Noven Therapeutics, LLC	68968-0525-8	8 POUCH in 1 CARTON (68968-0525-8) / 1 PATCH in 1 POUCH / 3.5 d in 1 PATCH	1998-08-07
Amneal	ACTIVELLA	estradiol; norethindrone acetate	TABLET;ORAL	020907	NDA	Amneal Pharmaceuticals LLC	60846-231-01	1 BLISTER PACK in 1 CARTON (60846-231-01) / 28 TABLET, FILM COATED in 1 BLISTER PACK	2019-05-01
Amneal	ACTIVELLA	estradiol; norethindrone acetate	TABLET;ORAL	020907	NDA	Amneal Pharmaceuticals LLC	60846-232-01	1 BLISTER PACK in 1 CARTON (60846-232-01) / 28 TABLET, FILM COATED in 1 BLISTER PACK	2019-05-01
Amneal	ACTIVELLA	estradiol; norethindrone acetate	TABLET;ORAL	020907	NDA AUTHORIZED GENERIC	Amneal Pharmaceuticals NY LLC	69238-1251-8	5 CARTON in 1 CELLO PACK (69238-1251-8) / 1 DIALPACK in 1 CARTON (69238-1251-6) / 28 TABLET, FILM COATED in 1 DIALPACK	2014-10-01
Amneal	ACTIVELLA	estradiol; norethindrone acetate	TABLET;ORAL	020907	NDA AUTHORIZED GENERIC	Amneal Pharmaceuticals NY LLC	69238-1252-8	5 CARTON in 1 CELLO PACK (69238-1252-8) / 1 DIALPACK in 1 CARTON (69238-1252-6) / 28 TABLET, FILM COATED in 1 DIALPACK	2014-10-01
Amneal	ACTIVELLA	estradiol; norethindrone acetate	TABLET;ORAL	020907	NDA	Amneal Pharmaceuticals NY LLC	69238-1609-6	1 BLISTER PACK in 1 CARTON (69238-1609-6) / 28 TABLET, FILM COATED in 1 BLISTER PACK	2019-01-07
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report identifies key suppliers of estradiol and norethindrone acetate, active pharmaceutical ingredients (APIs) critical for hormone replacement therapies and contraceptive formulations. Market analysis indicates a consolidated supplier landscape for both APIs, with established manufacturers possessing significant production capacity and regulatory approvals. The following sections detail identified suppliers, their product offerings, and relevant market considerations.

Who are the primary manufacturers of Estradiol?

The global supply of estradiol API is dominated by a limited number of specialized manufacturers. These companies possess the necessary expertise in steroid synthesis and adhere to stringent Good Manufacturing Practices (GMP) required for pharmaceutical-grade production.

Key Estradiol API Manufacturers:

Bayer AG: A significant player in the pharmaceutical industry, Bayer produces estradiol API for its internal downstream formulation and also supplies to the broader market. The company's operations are underpinned by extensive research and development in women's health.
Amneal Pharmaceuticals: Through acquisitions and organic growth, Amneal has established itself as a key supplier of various APIs, including estradiol. The company focuses on cost-effective manufacturing and a robust supply chain.
Novartis AG: While primarily known for finished dosage forms, Novartis has manufacturing capabilities for key APIs, including estradiol, supporting its extensive portfolio in endocrinology and women's health.
Pfizer Inc.: Pfizer is a major producer of a wide range of APIs, and estradiol is part of their steroid chemistry portfolio. Their global manufacturing network ensures broad accessibility.
Teva Pharmaceutical Industries Ltd.: Teva's API division manufactures estradiol, leveraging its scale to serve both its generic drug divisions and external clients.

Estradiol Production Capacity and Market Trends:

The production of estradiol involves complex multi-step chemical synthesis. Manufacturers often specialize in steroid hormones, requiring significant capital investment in dedicated facilities and specialized analytical equipment. Market reports suggest that pricing for estradiol API is influenced by raw material costs, regulatory compliance burdens, and the competitive landscape. Supply chain disruptions, as seen in recent global events, have highlighted the importance of diversified sourcing strategies for pharmaceutical companies. The primary production hubs are located in Europe and Asia, with stringent quality control measures enforced by regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Table 1: Estradiol API Suppliers Overview

Supplier Name	Primary Manufacturing Regions	Notes
Bayer AG	Germany, USA	Integrated API and finished product producer
Amneal Pharmaceuticals	USA, India	Focus on generic API supply
Novartis AG	Switzerland, USA	Broad API portfolio, including steroids
Pfizer Inc.	USA, Ireland, India	Global API manufacturing network
Teva Pharmaceutical Ind.	Israel, USA, India	Large-scale generic API production

What are the principal sources for Norethindrone Acetate API?

Norethindrone acetate, a synthetic progestin, is another critical API with a concentrated supplier base. Its synthesis requires precise control over stereochemistry and purity to meet pharmaceutical standards.

Key Norethindrone Acetate API Manufacturers:

Sun Pharmaceutical Industries Ltd.: A leading Indian pharmaceutical company, Sun Pharma is a significant producer of norethindrone acetate API. They serve both domestic and international markets, emphasizing quality and cost competitiveness.
Dr. Reddy's Laboratories Ltd.: Another prominent Indian API manufacturer, Dr. Reddy's produces norethindrone acetate API, leveraging its expertise in complex chemical synthesis and large-scale manufacturing.
AbbVie Inc.: While known for its branded pharmaceuticals, AbbVie (through its legacy Abbott Laboratories operations) has in-house API manufacturing capabilities, including for steroid hormones like norethindrone acetate, which are crucial for its contraceptive and women's health products.
Bristol Myers Squibb Company: BMS is involved in the production of select APIs, including norethindrone acetate, supporting its pharmaceutical portfolio.
Merck & Co., Inc.: Merck manufactures norethindrone acetate API, contributing to its broad range of hormonal and reproductive health products.

Norethindrone Acetate Production and Market Dynamics:

The manufacturing process for norethindrone acetate is chemically intensive and demands specialized facilities. Regulatory compliance, including FDA and EMA inspections, is paramount for suppliers. The market for norethindrone acetate API is characterized by a strong presence of Indian API manufacturers, who have established significant cost advantages due to lower labor and operational expenses. However, the quality and regulatory compliance of these suppliers are subject to rigorous international scrutiny. The demand for norethindrone acetate is closely linked to the global market for oral contraceptives and hormone replacement therapies. Fluctuations in birth rates and an aging population contribute to sustained demand.

Table 2: Norethindrone Acetate API Suppliers Overview

Supplier Name	Primary Manufacturing Regions	Notes
Sun Pharmaceutical Ind. Ltd.	India	Major global supplier of generic APIs
Dr. Reddy's Laboratories Ltd.	India	Strong focus on API development and manufacturing
AbbVie Inc.	USA, Ireland	Integrated API for internal and external use
Bristol Myers Squibb Company	USA	Select API production capabilities
Merck & Co., Inc.	USA, Europe	Broad API portfolio supporting various drug classes

What are the regulatory considerations for these API suppliers?

Suppliers of estradiol and norethindrone acetate APIs must adhere to stringent global regulatory requirements. These regulations ensure the safety, efficacy, and quality of the final drug products.

Key Regulatory Frameworks:

Good Manufacturing Practices (GMP): All API manufacturers must comply with GMP guidelines established by regulatory authorities such as the FDA (21 CFR Parts 210 and 211) and the EMA. GMP ensures that products are consistently produced and controlled according to quality standards.
Drug Master Files (DMFs): API suppliers typically submit DMFs to regulatory agencies. A DMF contains detailed information about the manufacturing process, facilities, quality control, and stability of the API. This allows drug product manufacturers to reference the DMF in their own marketing authorization applications.
Inspections and Audits: Regulatory agencies conduct periodic inspections of API manufacturing facilities to verify compliance with GMP. Pharmaceutical companies also conduct their own audits of API suppliers as part of their supplier qualification process.
Impurity Profiling and Control: Stringent limits are placed on impurities in APIs. Manufacturers must demonstrate robust methods for identifying, quantifying, and controlling process-related impurities and degradation products. This includes genotoxic impurities.
Supply Chain Security and Traceability: Regulations increasingly focus on ensuring the integrity of the pharmaceutical supply chain. This includes measures to prevent counterfeiting and ensure the traceability of APIs from the manufacturing site to the finished drug product.
Environmental Regulations: API manufacturing processes can generate waste. Suppliers must comply with local and international environmental regulations regarding waste disposal and emissions.

Impact of Regulations on Suppliers:

Compliance with these regulations represents a significant operational and financial commitment for API manufacturers. Investments in quality control systems, advanced analytical instrumentation, and employee training are continuous. Suppliers who demonstrate a strong regulatory track record and maintain high-quality standards are typically favored by pharmaceutical companies, as this reduces their own regulatory risk and expedites the approval process for their finished drug products. Failure to comply can result in warning letters, import alerts, and the suspension of manufacturing operations, significantly impacting supply.

What are the critical quality attributes for these APIs?

The quality of estradiol and norethindrone acetate APIs is determined by a set of critical quality attributes (CQAs) that directly impact the safety and efficacy of the final drug product.

Critical Quality Attributes for Estradiol and Norethindrone Acetate:

Assay (Purity): The API must meet a specified purity level, typically >98.0%, as determined by validated analytical methods (e.g., High-Performance Liquid Chromatography - HPLC). This ensures that the correct dose of the active ingredient is delivered.
Related Substances/Impurities: Limits are set for known and unknown impurities, including process-related impurities, degradation products, and enantiomeric impurities. These must be below specified thresholds, often determined by ICH guidelines (e.g., ICH Q3A for new drug substances).
Identification: The API must be unequivocally identified as estradiol or norethindrone acetate using methods such as Infrared Spectroscopy (IR), Mass Spectrometry (MS), or Nuclear Magnetic Resonance (NMR).
Water Content: The moisture content is controlled to prevent degradation and ensure stability. Karl Fischer titration is a common method for this determination.
Residual Solvents: Levels of organic solvents used during synthesis must be below specified limits as per ICH Q3C guidelines to avoid toxicity.
Particle Size Distribution (PSD): For solid dosage forms, PSD can significantly impact dissolution rates and bioavailability. Controlled PSD is often a specified parameter.
Chiral Purity: As these are chiral molecules, specific enantiomeric purity is crucial, as different enantiomers can have different pharmacological activities or toxicological profiles.
Polymorphism: The crystalline form of the API can affect its solubility, stability, and processability. Suppliers may need to control specific polymorphic forms.

Quality Control and Assurance:

API manufacturers implement rigorous quality control testing at various stages of production, from raw material inspection to final product release. Quality assurance systems oversee the entire manufacturing process, ensuring adherence to SOPs, batch record review, and deviation management. Certificate of Analysis (CoA) provided with each batch details the test results against approved specifications.

What are the supply chain risks associated with these APIs?

The pharmaceutical supply chain for specialized APIs like estradiol and norethindrone acetate is subject to various risks that can impact availability and cost.

Identified Supply Chain Risks:

Geopolitical Instability: Concentration of manufacturing in specific regions can expose the supply chain to disruptions from political unrest, trade wars, or international conflicts.
Raw Material Shortages: The synthesis of these complex molecules relies on specific chemical precursors. Disruptions in the supply of these raw materials, due to natural disasters, manufacturing issues at upstream suppliers, or regulatory changes, can halt API production.
Manufacturing Incidents: Plant shutdowns due to accidents, equipment failures, or quality control issues can lead to immediate shortages.
Regulatory Changes: New or revised regulations regarding manufacturing standards, impurity limits, or environmental controls can require manufacturers to invest in upgrades or cease production if they cannot comply.
Intellectual Property (IP) Disputes: While many basic steroid synthesis patents have expired, process patents and formulation patents can still lead to litigation that impacts the ability of certain suppliers to produce or sell their APIs.
Consolidation of Suppliers: A limited number of major suppliers can increase reliance on a few entities, making the supply chain vulnerable to their operational issues or strategic decisions.
Logistics and Transportation Issues: Global shipping disruptions, port congestion, or increased freight costs can delay deliveries and increase overall supply chain expenses.

Mitigation Strategies:

Pharmaceutical companies often mitigate these risks through multi-sourcing strategies, maintaining safety stock levels, and establishing strong relationships with multiple qualified suppliers. Due diligence on supplier financial stability, regulatory compliance history, and business continuity plans is also critical.

Key Takeaways

The supply of estradiol and norethindrone acetate APIs is concentrated among a limited number of global manufacturers, primarily based in Europe and India. Key players include Bayer, Amneal, Novartis, Pfizer, and Teva for estradiol, and Sun Pharma, Dr. Reddy's, AbbVie, Bristol Myers Squibb, and Merck for norethindrone acetate. Regulatory compliance with GMP, DMF submissions, and stringent quality attribute control (purity, impurities, identification) are paramount for API suppliers. Supply chain risks include geopolitical instability, raw material shortages, and manufacturing incidents, necessitating robust risk mitigation strategies such as multi-sourcing by pharmaceutical companies.

FAQs

What are the primary therapeutic uses for estradiol and norethindrone acetate?

Estradiol is a form of estrogen used in hormone replacement therapy (HRT) for menopausal symptoms, vaginal atrophy, and prevention of osteoporosis. Norethindrone acetate is a synthetic progestin used in hormonal contraceptives (birth control pills, patches, rings) and in HRT to counterbalance the effects of estrogen.

How do FDA and EMA regulations impact API manufacturing for these drugs?

The FDA and EMA mandate strict adherence to Good Manufacturing Practices (GMP), requiring detailed documentation of manufacturing processes, quality control testing, and facility inspections. This ensures the safety, efficacy, and quality of the APIs, influencing the cost and complexity of production.

What is the significance of Drug Master Files (DMFs) in the supply chain for these APIs?

DMFs are confidential documents submitted to regulatory agencies that detail the manufacturing process, facilities, and controls for an API. Pharmaceutical companies reference these DMFs in their drug product applications, streamlining the regulatory review process and providing assurance of API quality and consistency.

Are there any significant differences in quality standards between major regions like the USA, Europe, and India for these APIs?

While the fundamental GMP principles are harmonized globally, specific enforcement and interpretation can vary. Regulatory agencies like the FDA and EMA conduct rigorous inspections. Indian API manufacturers have significantly improved their quality systems to meet international standards, driven by the demand from regulated markets.

What are the typical lead times for sourcing Estradiol and Norethindrone Acetate APIs from these suppliers?

Lead times can vary significantly based on supplier inventory, production schedules, and order volume, but typically range from 2 to 6 months for standard orders. Urgent or large-volume requests may require longer lead times or necessitate expedited production efforts.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Guidance for Industry: ANDAs and DMFs. Retrieved from https://www.fda.gov/drugs/guidances-drug-regulatory-information/guidance-industry-andas-and-dmfs

[2] European Medicines Agency. (n.d.). Good manufacturing practice (GMP). Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-and-development/good-manufacturing-practice-gmp

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1995). Impurities: Guidelines for residual solvents Q3C(R8). Retrieved from https://www.ich.org/page/quality-guidelines

[4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2006). Impurities: Guidelines for new drug substances Q3A(R8). Retrieved from https://www.ich.org/page/quality-guidelines

[5] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) for Drugs. Retrieved from https://www.fda.gov/drugs/pharmaceutical-manufacturing/current-good-manufacturing-practice-cgmp-drugs

Suppliers and packagers for generic pharmaceutical drug: ESTRADIOL; NORETHINDRONE ACETATE

ESTRADIOL; NORETHINDRONE ACETATE

Estradiol and Norethindrone Acetate Drug Component Suppliers